Where is MedVision located?

MedVision is headquartered in Tampa, United States.

How many employees does MedVision have?

As of Apr 30, 2026, the latest employee count at MedVision is 48.

Is MedVision a funded company?

MedVision is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does MedVision rank among its competitors?

MedVision ranks 56th amongst 87 active competitors, of which 25 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Ventaris, which secured $30.7M in Jan, 2026.

Who are the top competitors of MedVision?

MedVision's top competitors include Olympus, ClearCam and SurgiQuest. Among them, Ventaris secured the most recent funding round in January, 2026.

MedVision - 2026 Company Profile, Team & Competitors

Company Details

Developer of smart surgical instruments for hospital and doctors use. The company has developed multiple surgical simulators that support the acquisition, and retention of procedural and psychomotor skills in laparoscopy, angiography, hysteroscopy, endoscopy, and others. Products include LapVision, AngioVision, HystVisoin, EndoVision, and many more.

Website: medvisionsim.com
Social
Email ID: *****@medvisiongroup.com
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

Tampa, United States

Stage

Unfunded

Ranked

56^th among 87 active competitors

Employee Count

48 as on Apr 30, 2026

Similar Companies

Olympus & 101 more

View MedVision's full profile

MedVision has not raised any funding rounds yet.

MedVision's employee count trend

MedVision has 48 employees as of Apr 26. Here is MedVision's employee count trend over the years:

Uncover MedVision's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MedVision include Olympus, ClearCam and SurgiQuest. Here is the list of Top 10 competitors of MedVision, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Olympus 1919, Tokyo (Japan), Public	Manufacturer of imaging and surgical products	-	ValueAct Capital, Sony	68/100
2nd	ClearCam 2018, Austin (United States), Seed	ClearCam: Improving surgical vision with in-vivo laparoscope lens cleaning	$7.73M	Austin Technology Incubator, Keiretsu Forum ... & 5 others	52/100
3rd	SurgiQuest 2006, City of Orange (United States), Acquired	Products for minimum invasive surgery	$59.1M	iandpdev.com, RC Capital & 7 others	45/100
4th	New View Surgical 2009, Boston (United States), Series B	Developer of minimally invasive systems for laparoscopic surgical procedures	$26.8M	Keiretsu Forum, Mid Atlantic Bio Angels & 13 others	44/100
5th	Claria Medical 2017, Mountain View (United States), Series A	Developer of minimally invasive surgical instruments	$8M	National Science Foundation, HHS & 1 others	44/100
6th	Eximis Surgical 2014, Louisville (United States), Series A	Minimally invasive surgical solution for specimen removal, improving patient outcomes	$40.6M	Questa Capital, Springboard Enterprises & 4 others	43/100
7th	Xenocor 2000, Salt Lake City (United States), Early Stage	Provider of Laparoscopic imaging system for surgeries	$10M	GenHenn Capital, Mountain Pacific Venture Partners ... & 2 others	40/100
8th	Genicon 1998, Winter Park (United States), Series B	Brandable domain name suitable for various industries and niche projects	$7.6M	Rand Capital, CEI & 2 others	39/100
9th	Corporis Medical 2015, Maastricht (Netherlands), Series B	Provider of diagnostic and wound closure devices for laparoscopic surgery	$6.67M	Brightlands Venture Partners, Unorthodox Ventures ... & 3 others	39/100
10th	Ventaris 2024, San Carlos (United States), Series A	Developer of a ureteroscopic system designed for kidney stone management	$30.7M	Longitude Capital, Vensana Capital & 3 others	37/100
56th	MedVision 2011, Tampa (United States), Unfunded	Developer of smart surgical instruments for hospital and doctors use	-	-	21/100